Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ambulance crews test Quick-Response blood clotting bundle for trauma patients

NCT ID NCT06891131

Knowledge-focused Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special combination of blood products and medication (fibrinogen, plasma, and tranexamic acid) can be given to trauma patients with life-threatening bleeding while still in the ambulance. The goal is to see if this approach is practical and safe. Only 10 adults with severe bleeding from injury will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fibrinogen, plasma, and tranexamic acid given as a transfusion bundle
What this could lead to
If successful, this could show that giving a specific combination of blood products and medication before reaching the hospital is feasible and may improve survival after severe bleeding.
What could go wrong
This is a very small, early feasibility study with only 10 participants. It is not designed to prove the treatment works, only that it can be given in an ambulance. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients in haemorrhagic shock that are being treated by one of the prehospital emergency systems of the Medical University of Graz (HEMS, emergency car)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * aged, or believed to be aged * 18 years or above * confirmed or suspected life-threatening bleeding from trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss) * need for volume replacement therapy. Exclusion Criteria: * patient with known recent history of thromboembolic events within the last 6 months * known or suspected pregnancy at presentation * patient with known refusal of a participation in this clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Haemorrhagic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

injury Shock, Hemorrhagic vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Haemorrhagic shock Trauma coagulopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of Graz

    RECRUITING

    Graz, 8043, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.